Raymond James analyst Andrew Cooper upgraded Natera to Outperform from Market Perform with a $58 price target. The setup moving through 2023 affords a healthy positive glide path with many potential catalysts that should keep markets excited over the coming quarters, Cooper tells investors in a research note. The analyst sees an an "encouraging" setup for the very rapidly growing oncology business as well as comfort that the core women’s health business is in a healthy position.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NTRA:
- Natera upgraded to Outperform from Market Perform at Raymond James
- Natera study data adds evidence for Signatera, says SVB Securities
- Natera’s CIRCULATE data looks strong, says Piper Sandler
- Natera announces publication of new study on ability of Signatera test
- Here’s why Natera is jumping in afternoon trading
